Novartis migraine drug not cost effective – UK price watchdog

Print pagePDF pageEmail page

Britain’s drug price watchdog on Thursday rejected Novartis’s migraine drug Aimovig for now, concluding in a draft decision that the medicine was not a cost-effective use of National Health Service resources.


Reuters: Health News … More ادامه مطلب

Leave a Reply

Time limit is exhausted. Please reload CAPTCHA.